CVC Catalyst将从 Blue Sea Capital、Arbogast家族及管理层手中收购 WillowWood的多数股权-动脉网

CVC Catalyst to Acquire Majority Stake in WillowWood from Blue Sea Capital, the Arbogast Family and Management

PR Newswire 等信源发布 2026-06-16 20:59



可切换为仅中文







MT. STERLING, Ohio

俄亥俄州斯特林山

，

June 16, 2026

2026年6月16日

/PRNewswire/ -- CVC Catalyst III ('CVC Catalyst') has agreed to acquire a majority stake in WillowWood Holdings Inc. ('WillowWood' or the 'Company'). CVC Catalyst will become the majority investor alongside Blue Sea Capital ('Blue Sea'), the Arbogast family and Management, who are reinvesting substantially alongside CVC.

/美通社/ -- CVC Catalyst III（“CVC Catalyst”）已同意收购WillowWood Holdings Inc.（“WillowWood”或“公司”）的多数股权。CVC Catalyst将成为多数投资者，与Blue Sea Capital（“Blue Sea”）、Arbogast家族以及管理层共同持股，后者将与CVC一起进行大量再投资。

Mahesh Mansukhani and Daniel Rubin (co-CEOs of WillowWood) will continue to lead the business and Ryan Arbogast, a fourth-generation member of the founding Arbogast family, will continue to play a key role in supporting the mission of the Company. Financial terms of the transaction were not disclosed..

Mahesh Mansukhani 和 Daniel Rubin（WillowWood 的联合首席执行官）将继续领导公司业务，而创始 Arbogast 家族的第四代成员 Ryan Arbogast 将继续在支持公司使命方面发挥关键作用。此次交易的财务条款未予披露。

WillowWood is one of the leading manufacturers of prosthetic products, including prosthetic liners, feet, knees, and other technologies, across the US and key European markets. Founded in 1907 in Mt. Sterling, Ohio by William E. Arbogast, a bilateral amputee who lost both legs in a railroad accident, WillowWood has spent more than 115 years committed to leveling the playing field for people experiencing limb loss through innovation and the pursuit of the best possible clinical outcomes.

WillowWood 是美国及欧洲主要市场领先的假肢产品制造商之一，其产品涵盖假肢接受腔衬套、假脚、假膝及其他技术。公司由威廉·E·阿博加斯特（William E. Arbogast）于1907年在俄亥俄州芒特斯特林创立。阿博加斯特本人是一名双侧截肢者，在一次铁路事故中失去了双腿。115年来，WillowWood 始终致力于通过创新和追求最佳临床效果，为截肢人士创造公平的生活条件。

The Company pioneered the gel liner, a critical interface between a patient's residual limb and their prosthesis, and remains the go-to liner brand for patients and prosthetists, offering approximately 1,000 SKUs alongside custom liner capabilities that solve the most challenging cases. This has been complemented by a fast-growing feet, knees and custom-fabrication portfolio to give amputees the mobility they are seeking..

该公司首创了凝胶衬垫，这是患者残肢与假肢之间的关键接口，并依然是患者和假肢师首选的衬垫品牌，提供约1,000种库存单位（SKU）以及定制衬垫服务，以解决最具挑战性的病例。此外，公司还不断扩展其快速增长的假脚、假膝及定制制造产品组合，为截肢者提供他们所需的行动能力。

'Since partnering with the Arbogast family in 2018, Daniel and I have been proud to build WillowWood into a leader in prosthetic products. This next chapter with CVC is about accelerating what we have built – bringing new products to patients faster and expanding internationally. We are grateful to Blue Sea Capital for their support and excited for what lies ahead,' said Mahesh Mansukhani, Chief Executive Officer of WillowWood..

“自2018年与阿博加斯特家族合作以来，丹尼尔和我为将WillowWood打造为假肢产品领域的领导者而感到自豪。与CVC合作的这一新篇章旨在加速我们已取得的成果——更快地向患者推出新产品，并拓展国际市场。我们感谢Blue Sea Capital的支持，并对未来的发展充满期待。”WillowWood首席执行官马赫什·曼苏卡尼表示。

Mansukhani and Rubin joined forces with the Arbogast family in 2018 and brought complementary commercial and operational expertise that allowed the Company to transform into a platform with a complete prosthetics products portfolio, upgraded commercial leadership, a broad R&D ecosystem and in-house manufacturing in Mt.

曼苏哈尼和鲁宾于2018年与阿博加斯特家族联手，带来了互补的商业和运营专业知识，使公司得以转型为一个拥有完整假肢产品组合、升级的商业领导团队、广泛研发生态系统以及位于蒙特内部制造能力的平台。

Sterling, Ohio and Mesa, Arizona. With 18 new product launches since 2021, WillowWood partners with leading national academic institutions to deliver the highest quality and outcomes to its patients, and its innovation is regularly awarded by industry prizes such as the distinguished Thranhardt award which will recognize WillowWood's research into protecting limb health at the upcoming 2026 AOPA National Assembly. .

俄亥俄州斯特林和亚利桑那州梅萨。自2021年以来，WillowWood已推出18款新产品，并与领先的全国性学术机构合作，为患者提供最高品质的产品和服务及最佳疗效。其创新成果屡获行业奖项认可，例如备受瞩目的Thranhardt奖，该奖项将在即将举行的2026年美国假肢与矫形器协会（AOPA）全国大会上表彰WillowWood在保护肢体健康方面的研究。

'WillowWood is a business of rare quality, built over more than a century into the leader in its field. Mahesh, Daniel, and the team have created a differentiated platform with a clear runway ahead, and we are delighted to be partnering with them, the Arbogast family, and Blue Sea Capital to support its next phase,' said Cathrin Petty, Managing Partner and Global Head of Healthcare at CVC..

“WillowWood 是一家品质卓绝的企业，经过百余年的发展，已成为其所在领域的领导者。Mahesh、Daniel 及其团队打造了一个具有差异化优势的平台，未来增长路径清晰明确。我们很高兴能与他们、Arbogast 家族以及 Blue Sea Capital 携手合作，共同支持其进入下一个发展阶段。”CVC 的管理合伙人兼全球医疗健康行业负责人 Cathrin Petty 表示。

CVC Catalyst plans to accelerate WillowWood's next phase of growth. The partnership will invest in research and development and new product innovation, and will pursue an active M&A strategy to broaden the Company's offering and geographic reach. A particular priority will be expanding WillowWood's international presence, including building a direct commercial footprint in Europe.

CVC Catalyst 计划加速 WillowWood 下一阶段的成长。双方将投资于研发与新产品创新，并采取积极的并购策略，以拓宽公司的产品组合和地理覆盖范围。工作重点之一将是扩大 WillowWood 的国际布局，包括在欧洲建立直接的商业存在。

WillowWood will benefit from CVC Healthcare's global scale, international network, and MedTech expertise..

WillowWood 将受益于 CVC Healthcare 的全球规模、国际网络以及医疗技术专业专长。

'The opportunity ahead in Europe is substantial, and CVC's geographic footprint and sector expertise are well suited to helping WillowWood build a direct presence and scale internationally. It is businesses at this type of inflection point that we are looking to support with CVC Catalyst, and we look forward to working with the team as they bring new products to more patients in these markets,' said Phil Robinson, Partner at CVC..

“欧洲市场蕴藏着巨大的机遇，而CVC的地理布局和行业专长非常有助于帮助WillowWood建立直接的市场存在并实现国际规模化扩张。我们希望通过CVC Catalyst支持处于此类转折点的企业，并期待与团队合作，共同将新产品带给这些市场的更多患者。”CVC合伙人Phil Robinson表示。

'We at Blue Sea are both proud and humbled to have supported Mahesh, Daniel, and the Arbogast family in accelerating WillowWood's growth, and we are even more energized by the opportunity ahead,' said Erin Lansky, Principal at Blue Sea Capital and member of the Board of Directors of WillowWood.

“我们蓝海资本团队既为支持马赫什、丹尼尔以及阿博加斯特家族加速推动WillowWood的增长而感到自豪与荣幸，也对未来的机遇倍感振奋，”蓝海资本主管、WillowWood董事会成员艾琳·兰斯基表示。

CVC Catalyst is CVC's dedicated mid-market private equity strategy, seeking leading businesses with strong market positions and compelling long-term fundamentals. CVC has a long and successful track record of investing in MedTech and healthcare businesses, with a proven playbook – demonstrated through investments including Rayner, Spectrum, and Therakos – encompassing R&D acceleration, commercial build-out, international expansion, and targeted M&A.

CVC Catalyst 是 CVC 专注于中等规模市场的私募股权策略，旨在寻找拥有强大市场地位和令人信服的长期基本面的领先企业。CVC 在医疗科技和医疗保健领域的投资方面拥有悠久而成功的记录，并具备一套经证实的投资方法论——通过对 Rayner、Spectrum 和 Therakos 等企业的投资得以体现——涵盖加速研发、商业化拓展、国际扩张以及有针对性的并购活动。

WillowWood is a natural fit for the Catalyst mandate, combining over a century of prosthetics innovation with a strongly aligned management team and significant runway for growth..

WillowWood 与 Catalyst 的使命高度契合，它不仅拥有超过一个世纪的假肢创新历史，还拥有一支高度协同的管理团队以及巨大的增长潜力。

Closing of the transaction is subject to approval by the relevant regulatory authorities and is expected in the third quarter of 2026.

交易的完成须获得相关监管机构的批准，预计将于2026年第三季度完成。

About WillowWood

关于 WillowWood

Founded in 1907 by William Arbogast and headquartered in Mount Sterling, Ohio, WillowWood is one of the world's leading prosthetics companies, with a strong position in prosthetic liners and a growing presence in prosthetic feet and knees. The Company serves orthotics and prosthetics clinics and practitioners across the United States and internationally, with a reputation for clinical innovation and product quality built over more than a century of continuous operation.

WillowWood 由 William Arbogast 于 1907 年创立，总部位于俄亥俄州芒特斯特林，是全球领先的假肢公司之一，在假肢衬套领域占据强势地位，并在假肢脚板和膝关节领域的影响力日益增强。该公司服务于美国及国际各地的矫形与假肢诊所和从业者，凭借一个多世纪持续运营所积淀的临床创新和产品质量声誉而广受认可。

For further information, please visit .

如需更多信息，请访问。

www.willowwood.com

。

About Blue Sea Capital

关于蓝海资本

Blue Sea Capital (

蓝海资本（

www.blueseacapital.com

) is a private equity firm based in West Palm Beach, Florida, that invests in growth-oriented lower middle market healthcare companies valued up to $500 million. With over $1.5 billion in assets under management, Blue Sea Capital's strategy is to partner with talented leaders and differentiated companies, typically as the first or second institutional investor, and deliver strategic and operational value-add that drives growth acceleration, industry outperformance and business transformation..

）是一家总部位于佛罗里达州西棕榈滩的私募股权公司，专注于投资估值高达5亿美元的、以增长为导向的中小型医疗保健企业。Blue Sea Capital 管理资产规模超过15亿美元，其战略是与才华横溢的管理团队和具有差异化优势的公司建立合作伙伴关系，通常作为首家或第二家机构投资者介入，并通过提供战略与运营层面的增值支持，推动企业加速增长、实现行业领先表现以及业务转型。

About CVC

关于CVC

CVC is a leading global private markets manager with a network of 29 office locations throughout EMEA, the Americas, and Asia, with approximately €209 billion of assets under management. CVC has seven complementary strategies across private equity, secondaries, credit and infrastructure, for which CVC funds have secured commitments of over €257 billion from some of the world's leading pension funds and other institutional investors.

CVC 是一家领先的全球私募市场管理机构，在欧洲、中东和非洲（EMEA）、美洲以及亚洲拥有由 29 个办公室组成的网络，管理资产规模约为 2,090 亿欧元。CVC 在私募股权、二手份额、信贷和基础设施领域布局了七项互补策略，其基金已从全球一些领先的养老基金和其他机构投资者处获得超过 2,570 亿欧元的承诺出资。

Funds managed or advised by CVC's private equity strategy are invested in approximately 150+ companies worldwide, which have combined annual sales of over €240 billion and employ over 660,000 people. For further information about CVC please visit: .

由CVC私募股权策略管理或提供顾问服务的基金已投资于全球150多家公司，这些公司的年销售总额超过2,400亿欧元，员工总数超过66万人。如需了解更多关于CVC的信息，请访问：。

https://www.cvc.com/

. Follow us on

关注我们

领英

。

Media Contact:

媒体联系人：

Hugo Rubin

雨果·鲁宾

Director of Marketing

市场总监